Rilmenidine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rilmenidine
Accession Number
DB11738
Type
Small Molecule
Groups
Approved, Investigational
Description

Rilmenidine has been used in trials studying the treatment of Hypertension and Chronic Kidney Disease.

Structure
Thumb
Synonyms
  • HYPERIUM
Product Ingredients
IngredientUNIICASInChI Key
Rilmenidine Phosphate59QD64Q32M85409-38-7ZJCOWRFWZOAVFY-UHFFFAOYSA-N
Categories
UNII
P67IM25ID8
CAS number
54187-04-1
Weight
Average: 180.251
Monoisotopic: 180.126263143
Chemical Formula
C10H16N2O
InChI Key
CQXADFVORZEARL-UHFFFAOYSA-N
InChI
InChI=1S/C10H16N2O/c1-2-7(1)9(8-3-4-8)12-10-11-5-6-13-10/h7-9H,1-6H2,(H,11,12)
IUPAC Name
N-(dicyclopropylmethyl)-4,5-dihydro-1,3-oxazol-2-amine
SMILES
C1CC1C(NC1=NCCO1)C1CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAlpha-2A adrenergic receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid may increase the hypotensive activities of Rilmenidine.
AcebutololThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acebutolol.
AceclofenacThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acemetacin.
AcepromazineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acepromazine.
Acetylsalicylic acidThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acetylsalicylic acid.
AlclofenacThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Alclofenac.
AlfuzosinAlfuzosin may increase the hypotensive activities of Rilmenidine.
AliskirenAliskiren may increase the hypotensive activities of Rilmenidine.
AlminoprofenThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Alminoprofen.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C11120
PubChem Compound
68712
PubChem Substance
347828096
ChemSpider
61963
BindingDB
50070328
ChEBI
8862
ChEMBL
CHEMBL289480
Wikipedia
Rilmenidine
ATC Codes
C02AC06 — Rilmenidine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4WithdrawnTreatmentChronic Kidney Disease (CKD) / High Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.34 mg/mLALOGPS
logP1.43ALOGPS
logP1.58ChemAxon
logS-2.1ALOGPS
pKa (Strongest Basic)7.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area33.62 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity49.79 m3·mol-1ChemAxon
Polarizability20.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as oxazolines. These are organic compounds containing 1,3-oxazoline, a five-membered ring with a nitrogen and an oxygen atoms at the 1- and 3-position, respectively. Additionally, it contains two double bonds.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azolines
Sub Class
Oxazolines
Direct Parent
Oxazolines
Alternative Parents
Isoureas / Propargyl-type 1,3-dipolar organic compounds / Oxacyclic compounds / Carboximidamides / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Oxazoline / Isourea / Oxacycle / Azacycle / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboximidamide / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
isourea (CHEBI:8862)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Zhu QM, Lesnick JD, Jasper JR, MacLennan SJ, Dillon MP, Eglen RM, Blue DR Jr: Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A-adrenoceptor transgenic mice. Br J Pharmacol. 1999 Mar;126(6):1522-30. [PubMed:10217548]

Drug created on October 20, 2016 14:43 / Updated on November 02, 2018 09:01